Steve Colletti
Net worth: - $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ram Aiyar | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 4 years |
Nessan Bermingham | M | 51 |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 6 years |
Jean-Francois Formela | M | 67 |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 6 years |
Vineet Agarwal | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 3 years |
Andrew Fraley | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | - |
Shelby Walker | F | - | 1 years | |
Ali Behbahani | M | 45 |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 1 years |
Timothy Pearson | M | 56 | 1 years | |
Rachel Meyers | M | - | 1 years | |
Todd Chappell | M | - | 1 years | |
Ommer Chohan | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | - |
David Lucchino | M | 56 | 1 years | |
Omar Khwaja | M | 54 |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | - |
Colin Walsh | M | 38 |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 4 years |
Nikola Trbovic | - | - |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | 5 years |
Aindrea Campbell | M | - | 3 years | |
Subodh S. Deshmukh | M | - | 3 years | |
Lincoln Germain | M | - | 3 years | |
Stephanie Engels | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jed Dean | M | - | 8 years | |
Zachariah Serber | M | 49 | 9 years | |
Steven J. Chu | M | 76 | 6 years | |
Travis Murdoch | M | - | 4 years | |
Dale Pfost | M | - |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | 2 years |
Mina Kim | F | 50 | 2 years | |
Thong Le | M | 48 |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | - |
David Pompliano | M | - |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | - |
Joshua Hoffman | M | - | 8 years | |
Christine Gorjanc | F | 67 | 1 years | |
Ryan Robinson | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 3 years |
Shiva Amiri | M | - | 4 years | |
Nikola Trbovic | M | - |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | 2 years |
Niraj Javeri | M | 43 | 1 years | |
Enakshi Singh | F | 46 | 8 years | |
Aaron Kimball | M | - | 8 years | |
Donald Marvin | M | - |
Lodo Therapeutics Corp.
Lodo Therapeutics Corp. BiotechnologyHealth Technology Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY. | 1 years |
Richard Pieters | M | - | 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 31 | 83.78% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Steve Colletti
- Personal Network